Fig. 2From: Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studiesSnapshot virologic outcomes at Week 48 overall and by age. TANGO and SALSA pooled ITT-E population. CAR current antiretroviral regimen, c/mL copies/mL, DTG dolutegravir, ITT-E intention-to-treat exposed, 3TC lamivudineBack to article page